-+ 0.00%
-+ 0.00%
-+ 0.00%
Changes in Hong Kong stocks | Genting Xinyao (01952) rose more than 3%, two new drugs first introduced Medicare, and Weishipin® is safe to use in the treatment of ulcerative colitis
Share
Listen to the news

The Zhitong Finance App learned that Genting Xinyao (01952) rose more than 3%. As of press release, it had risen 3.45% to HK$26.42, with a turnover of HK$85,823,400.

According to news, on November 14, Genting Xinyao's Weishipin® (arginine etramide tablets) and Yika ® (injectable eracycline hydrochloride) passed national health insurance negotiations and were included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2026)” for the first time. The new catalogue will be officially implemented on January 1, 2027. At the same time, it successfully renewed its contract for IgA nephropathy due to the therapeutic drug resistant to fukang® (budesonide enteric capsules) and remains on the catalogue.

So far, three Genting Xinyao products have entered the national medical insurance catalogue, covering fields such as ulcerative colitis, complicated abdominal infections, and IgA nephropathy. Among them, Weishiping® was covered by medical insurance in the first year of marketing. According to reports, Weishipin ® is the first and only Sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of UC in China. In the largest Asian multi-center phase III clinical study (ENLIGHT UC) completed to date for moderate to severe UC patients, the mucosal healing rate reached 51.9% during 52 weeks of treatment, and long-term follow-up showed good drug safety.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending